admin
Gov. JB Pritzker told CBS Mornings this week that he was diagnosed with Type 2 diabetes about two years ago and that a GLP‑1 medication, plus diet and walking, helped him drop roughly 80 pounds and stop using insulin. The governor’s revelation is personal — and political — and it raises honest questions about health, state policy, and who pays the bill when new drugs suddenly change the game.
Pritzker’s disclosure: GLP‑1, weight loss, and improved labs
Pritzker said his doctor warned he could be on insulin for life, then recommended a GLP‑1. He described how, after a few days on the medicine, his appetite changed and the pounds began to come off. The governor’s office says he is “no longer on insulin” and that his bloodwork now shows levels outside the diabetic or prediabetic range. That’s great news for his health — and for his campaign trail appearance — but the governor declined to name the specific drug he used.
State coverage and the price tag Illinois is carrying
Here’s where it stops being only a personal health win and starts being a public policy headache. Illinois expanded coverage of GLP‑1 medicines for some state employees and others, and Pritzker has defended that policy. These drugs can help people with Type 2 diabetes, but they’re expensive. When elected officials cheer coverage without answering cost-control questions, taxpayers deserve to know how much programs will add to state budgets and whether coverage crowds out more urgent needs.
Who decides which drugs taxpayers underwrite?
Decisions about coverage are not just medical; they are budgetary and moral. If a drug is life‑saving for diabetes, good — make it accessible. If it’s being used broadly for chronic weight management at huge cost, states must weigh tradeoffs. The debate over GLP‑1s has exposed the tension: better health outcomes versus sticker shock in state coffers. Lawmakers should explain the math, not just let celebrities and governors set the tone with feel‑good TV moments.
Bottom line: transparency, common sense, and the politics of a slimmer governor
Gov. Pritzker’s health improvement is plausible and worth celebrating on a human level. But his public disclosure lands at a moment when he’s boosting his national profile and spending on Democratic House races. That makes transparency about which drug, what costs, and what the long‑term plan is more than a medical footnote — it’s a governance issue. If Illinois wants to lead on health policy, it should do so with open books, clear rules for coverage, and a plan to protect taxpayers while helping patients. Voters should expect nothing less.
